Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Opinion|Videos|August 2, 2025
Joseph Song, MD, describes his experience using the CVAC device
Author(s)Joseph Song, MD
Fact checked by: Hannah Clarke
Joseph Song, MD, details his experience using the CVAC device for SURE procedures.
Advertisement
In a recent interview with Urology Times®, Joseph Song, MD, details his experience using the CVAC device for Steerable Ureteroscopic Renal Evacuation (SURE) procedures.
Song is a urologist with Georgia Urology in Atlanta, Georgia.
Advertisement
Related to this article
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
Factors shaping PSMA-PET agent selection in prostate cancer
2
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
3
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
4
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
5